ASX Stock

At Trader Dealer we understand the importance of information. You can use our handy company information finder to get key fundamental data about any company listed on the ASX.

Simply enter the stock code or the name of the company you are interested in for ASX share price information, company size, research analyst forecast, share and financial ratios, as well as a business and financial summary.

Don’t know the ASX code of the stock you want? Just click on the letter below for a full alphabetical listing.


Enter ASX Stock Code

Bookmark Page !



View all Companies by Letters

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z 


 
 

CSL Limited
Industry Group: Biotechnology / Medical Research - Biotechnology

Trade Online with Trader Dealer

Sorry, No Chart Available.

Business Summary
CSL Limited is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and develops plasma products. Intellectual Property Licensing includes revenue and associated expenses from the licensing of Intellectual Property generated by the Company to unrelated third parties. Other Human Health consists of CSL Bioplasma and CSL Biotherapies. The Company operates in four geographic areas: Australia, the United States of America, Switzerland, and Germany. In December 2010, the United States Food and Drug Administration (FDA) approved GARDASIL. On February 18, 2011 CSL Behring announced the United States FDA had granted marketing approval for Corifact Factor XIII concentrate (Human) for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency.

Financial Summary
BRIEF: For the fiscal year ended 30 June 2011, CSL Limited's revenue decreased 7% to A$4.32B. Net income decreased 11% to A$940.6M. Revenue reflect an decrease in income from CSL Behring segment and lower income from other human segment of the group. Net income also reflects an increase in research & development expenses and lower gross profit margin. CSL Limited is engaged in the research, development and manufacture of vaccines.

Business Address
IMark Dehring
Investors Relation
45 Poplar Road
Victoria, VIC 3052
Phone: 61-3-93891911
Fax: 61-3-93891434
http://www.csl.com.au/

ASX Share Price Information
Current Price 30.44
Current Price Date 08/02/2012
52 Week Hi/Low 37.87 - 26.12
Avg Volume Last ten Days 2.47
ASX Company Sizing
Market Cap 15809.68
Revenues 15728.53
EBITDA 1378.69
Net Income 940.60
Number of Employees 10411
Enterprise Value 15728.53
Research Analyst Forecast
Consensus Recommendation Outperform
Target Price 34.33882
LT Growth Rate 10.7408
Projected P/E 15.60457
Sales 4620.47110
EPS 1.95071
Profit 1317.03280
DPS 0.88524
Share Ratios
EPS 1.73603
RPS 7.97615
BV per Share 6.94375
Cash per Share 0.94771
Cashflow per Share 2.04258
Cashflow per Share 0.80000
Financial Ratios
Gross Margin 49.16190
ROE 23.93523
Price/Sales 3.65832
P/E 17.53426
P/Book 4.38380